Literature DB >> 15716700

Effects of glucose and insulin on the development of oxidative stress and hypertension in animal models of type 1 and type 2 diabetes.

Adil El Midaoui1, Jacques de Champlain.   

Abstract

OBJECTIVES: To investigate whether glucose or insulin is the cause of increases in oxidative stress and blood pressure in insulin-resistant animals, and to evaluate the effects of alpha-lipoic acid (LA) on the production of the superoxide anion (O2-) in the aorta and blood pressure elevations in various models of diabetes.
METHODS: Two models of arterial hypertension combined with insulin resistance state and one model of insulin-dependent diabetes were studied in chronically glucose-fed rats (10% in drinking water), in animals chronically treated simultaneously with insulin (9 mU/kg per min with osmotic pumps) and glucose, and in rats initially treated with streptozotocin (50 mg/kg) and glucose during 4 weeks. These three groups of rats were treated either with a normal chow diet or with LA-supplemented diet. The oxidative stress was evaluated by the O2- production using the lucigenin-enhanced chemiluminescence method either in aortic or cultured smooth muscle cells from 12-week-old normotensive rats. Fasting blood glucose and insulin levels were measured after 4 weeks.
RESULTS: At the end of the study, plasma levels of insulin and glucose as well as the insulin resistance index were found to be significantly higher in glucose-fed rats or in rats treated with insulin plus glucose compared with control rats (P < 0.01). Plasma glucose levels were elevated (P < 0.01) but plasma insulin levels were not modified in streptozotocin- and glucose-treated rats. Systolic blood pressure and aorta O2- production were found to be significantly higher in either glucose-fed rats (+20%) or in insulin plus glucose-treated rats (+24%) as compared with control rats (P < 0.01). Streptozotocin-induced diabetes with glucose treatment was not accompanied by increases in systolic blood pressure or in aortic O2- production. Rises in systolic blood pressure and in aortic O2- production were significantly attenuated either in glucose-fed (+10.3%) or in insulin plus glucose-fed (+8.7%) rats treated with LA. The simultaneous treatment with LA also attenuated the rise in insulin levels as well as in insulin resistance either in glucose-fed rats or in insulin plus glucose-treated rats. Moreover, LA was found to prevent the marked increases in O2- production in cultured smooth muscle cells chronically treated with high insulin combined or not with high glucose levels.
CONCLUSIONS: These findings demonstrate that elevated plasma glucose levels alone do not induce vascular oxidative stress and hypertension unless it is combined with high level of insulin. The finding that the treatment with LA, a potent antioxidant, was efficacious in preventing oxidative stress and hypertension in diabetic models of insulin resistance suggests an important participation of oxidative stress in the development of hypertension in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15716700     DOI: 10.1097/01.hjh.0000160215.78973.ba

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

Review 1.  Nutritional supplements and their effect on glucose control.

Authors:  Tanya Lee; Jean-Jacques Dugoua
Journal:  Curr Diab Rep       Date:  2011-04       Impact factor: 4.810

2.  Glycemic load is associated with oxidative stress among prevalent maintenance hemodialysis patients.

Authors:  Chutatip Limkunakul; Mary B Sundell; Brianna Pouliot; Amy J Graves; Ayumi Shintani; Talat A Ikizler
Journal:  Nephrol Dial Transplant       Date:  2013-12-17       Impact factor: 5.992

3.  Impaired coronary function in Wistar Ottawa Karlsburg W rats-a new model of the metabolic syndrome.

Authors:  Olaf Grisk; Tillmann Frauendorf; Torsten Schlüter; Ingrid Klöting; Beate Kuttler; Alexander Krebs; Jan Lüdemann; Rainer Rettig
Journal:  Pflugers Arch       Date:  2007-05-01       Impact factor: 3.657

4.  Kinin B1 receptor enhances the oxidative stress in a rat model of insulin resistance: outcome in hypertension, allodynia and metabolic complications.

Authors:  Jenny Pena Dias; Sébastien Talbot; Jacques Sénécal; Pierre Carayon; Réjean Couture
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

5.  The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance.

Authors:  J P Dias; M A Ismael; M Pilon; J de Champlain; B Ferrari; P Carayon; R Couture
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

6.  Signaling of reactive oxygen and nitrogen species in Diabetes mellitus.

Authors:  Igor Afanas'ev
Journal:  Oxid Med Cell Longev       Date:  2010-11-01       Impact factor: 6.543

7.  The effect of varying levels of purified condensed tannins on performance, blood profile, meat quality and methane emission in male Bapedi sheep fed grass hay and pellet-based diet.

Authors:  J W Ngámbi; M J Selapa; D Brown; T G Manyelo
Journal:  Trop Anim Health Prod       Date:  2022-08-12       Impact factor: 1.893

8.  Effects of Brown Seaweed (Sargassum polycystum) Extracts on Kidney, Liver, and Pancreas of Type 2 Diabetic Rat Model.

Authors:  Mahsa Motshakeri; Mahdi Ebrahimi; Yong Meng Goh; Hemn Hassan Othman; Mohd Hair-Bejo; Suhaila Mohamed
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-08       Impact factor: 2.629

9.  Impact of the Type of Continuous Insulin Administration on Metabolism in a Diabetic Rat Model.

Authors:  A Schaschkow; C Mura; S Dal; A Langlois; E Seyfritz; C Sookhareea; W Bietiger; C Peronet; N Jeandidier; M Pinget; S Sigrist; E Maillard
Journal:  J Diabetes Res       Date:  2016-07-18       Impact factor: 4.011

10.  Beneficial Effects of Alpha-Lipoic Acid on Hypertension, Visceral Obesity, UCP-1 Expression and Oxidative Stress in Zucker Diabetic Fatty Rats.

Authors:  Adil El Midaoui; I George Fantus; Ali Ait Boughrous; Réjean Couture
Journal:  Antioxidants (Basel)       Date:  2019-12-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.